SpringerLink
Log in

Zastaprazan: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Zastaprazan (JAQBO®) is a next-generation potassium-competitive acid blocker being developed by Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical, for the treatment of acid-related diseases. Zastaprazan binds directly to proton pumps in a competitive manner to reduce gastric acid secretion, allowing for a quick onset of action. On 24 April 2024, zastaprazan received approval in South Korea for the treatment of erosive gastroesophageal reflux disease (GERD). Zastaprazan is also undergoing phase III development for the treatment of gastric ulcer and for the prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer. This article summarizes the milestones in the development of zastaprazan leading to this first approval for erosive GERD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Katzka DA, Pandolfino JE, Kahrilas PJ. Phenotypes of gastroesophageal reflux disease: where Rome, Lyon, and Montreal meet. Clin Gastroenterol Hepatol. 2020;18(4):767–76.

    Article  CAS  PubMed  Google Scholar 

  2. Armstrong D. Potassium-competitive acid blockers and gastroesophageal reflux disease. Gastroenterol Hepatol. 2023;19(5):295–8.

    Google Scholar 

  3. Onconic Therapeutics. Onconic Therapeutics receives MFDS approval for JAQBO, a new treatment for gastroesophageal reflux disease (GERD) [media release]. 25 Apr 2024. https://www.prnewswire.com/in/news-releases/onconic-therapeutics-receives-mfds-approval-for-jaqbo-a-new-treatment-for-gastroesophageal-reflux-disease-gerd-302127478.html.

  4. Onconic Therapeutics. JAQBO 20 mg tablets (zastaprazan citrate): Korean prescribing information. 2024.

  5. Livzon Pharmaceuticals. Voluntary announcement entering into the license agreement [media release]. 10 Mar 2023. http://www1.hkexnews.hk.

  6. Ku JM, Cho JH, Kim K, et al. JP-1366: a novel and potent potassium-competitive acid blocker that is effective in the treatment of acid-related diseases. Pharmacol Res Perspect. 2023;11(3): e01090.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hwang I, Ji SC, Oh J, et al. Randomised clinical trial: safety, tolerability, pharmacodynamics and pharmacokinetics of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in healthy subjects. Aliment Pharmacol Ther. 2023;57(7):763–72.

    Article  CAS  PubMed  Google Scholar 

  8. Oh J, Kim H, Cheung DY, et al. Randomised, double-blind, active-controlled phase 3 study to evaluate the efficacy and safety of zastaprazan compared with esomeprazole in erosive oesophagitis [zastaprazan erosive reflux oesophagitis-1 study (ZERO-1)] [abstract no. OP050]. United Eur Gastroenterol J. 2023;11(Suppl 8):54–6.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Hannah A. Blair

Authors
  1. Hannah A. Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hannah A. Blair.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of Interest

During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah A. Blair is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 194 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blair, H.A. Zastaprazan: First Approval. Drugs (2024). https://doi.org/10.1007/s40265-024-02057-w

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40265-024-02057-w

Search

Navigation